Novartis AG
NVS
$119.31
$0.760.64%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.49% | 34.15% | -66.77% | 81.09% | 40.16% |
| Total Depreciation and Amortization | 3.94% | -0.52% | 110.87% | -11.70% | -11.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.91% | 18.73% | 139.83% | -19.38% | 202.69% |
| Change in Net Operating Assets | 426.00% | 14.02% | 65.40% | -10.73% | 73.40% |
| Cash from Operations | 36.70% | 60.93% | 64.63% | 16.88% | 36.33% |
| Capital Expenditure | -27.31% | -11.89% | -37.44% | -22.99% | -15.56% |
| Sale of Property, Plant, and Equipment | -97.30% | 900.00% | -71.34% | -98.04% | 825.00% |
| Cash Acquisitions | 49.47% | -- | -7,000.00% | 98.32% | -3,193.00% |
| Divestitures | 57.69% | 89.47% | 8,300.00% | 250.00% | -262.50% |
| Other Investing Activities | -171.04% | 246.70% | -49.67% | -100.21% | 144.79% |
| Cash from Investing | 30.06% | 136.71% | -72.33% | 83.09% | -204.56% |
| Total Debt Issued | -72.06% | -54.43% | -104.40% | -- | -- |
| Total Debt Repaid | 69.71% | -1,510.45% | -228.13% | 57.10% | -185.40% |
| Issuance of Common Stock | -20.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -67.95% | -147.13% | -119.90% | -75.63% | 45.35% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.81% | -2.42% | -- | -- | -- |
| Other Financing Activities | -760.00% | 309.09% | -428.21% | -101.23% | -126.60% |
| Cash from Financing | -62.91% | -65.53% | -393.57% | 54.09% | 12.02% |
| Foreign Exchange rate Adjustments | 1,223.53% | 242.86% | -296.25% | 206.02% | -3,300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.82% | -11.95% | -317.61% | 275.39% | -40.45% |